Inovio Q2 net loss narrows to $23.5M; BLA for INO-3107 on track for 2H25 submission

INOVIO PHARMACEUTICALS, INC.

2025-Q2 EPS reported -$1.12 vs consensus -$0.62 ▼ miss (-82.0%)

Net loss $23.5M ($0.61/share) vs $32.2M ($1.19/share) YoY; total operating expenses $23.1M down from $33.3M.
Completed CELLECTRA 5PSP device DV testing; requested rolling BLA submission for INO-3107 by year end.
Cash, cash equivalents, and short-term investments $47.5M at June 30; plus $22.5M from July offering, supporting ops into Q2 2026.
Long-term INO-3107 data published: 86% of patients had 50-100% reduction in surgeries by Year 2; mean surgeries reduced from 4.1 to 0.9.
R&D expenses fell to $14.5M from $23.1M, reflecting lower drug manufacturing and clinical costs.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.